{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:37:42Z","timestamp":1777934262249,"version":"3.51.4"},"reference-count":39,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T00:00:00Z","timestamp":1458000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Trastuzumab-related cardiotoxicity has been a major concern in clinical practice, since observational studies have shown higher incidences than that reported in clinical trials. We aim to measure the incidence of trastuzumab-related cardiotoxicity in patients with early and metastatic breast cancer in the south of Brazil.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Multicenter prospective observational study, which included 109 patients with early or metastatic HER-2+ breast cancer undergoing any trastuzumab-based regimen. Cardiac events were measured by transthoracic echocardiography assessments and by signs and symptoms of heart failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Trastuzumab-related cardiotoxicity was observed in 58 patients (53.2%). Emergency and hospitalization admissions were necessary in seven and three patients, respectively, due to symptoms of heart failure. One patient died in consequence of trastuzumab-related cardiotoxicity. In total, trastuzumab was discontinued in 31.2% of patients, of which almost a third could not return to treatment. In this study, no risk factors were significantly associated with the development of cardiotoxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The incidence of TRC and trastuzumab's early discontinuation observed was significantly higher in comparison with other studies. These findings endorse the fact that trastuzumab-related cardiotoxicity is a relevant adverse reaction, and therefore, cardiac dysfunction's monitoring must be highlighted in order to allow a safe use of trastuzumab in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155216639755","type":"journal-article","created":{"date-parts":[[2016,3,16]],"date-time":"2016-03-16T20:19:08Z","timestamp":1458159548000},"page":"264-272","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Observational study of trastuzumab-related cardiotoxicity in early and metastatic breast cancer"],"prefix":"10.1177","volume":"23","author":[{"given":"LR","family":"Grazziotin","sequence":"first","affiliation":[{"name":"Hospital de Cl\u00ednicas de Porto Alegre, Porto Alegre, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PD","family":"Picon","sequence":"additional","affiliation":[{"name":"Hospital de Cl\u00ednicas de Porto Alegre, Porto Alegre, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,3,15]]},"reference":[{"key":"bibr1-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052306"},{"key":"bibr2-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101"},{"key":"bibr3-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-015-0070-y"},{"key":"bibr4-1078155216639755","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2012.28549"},{"key":"bibr5-1078155216639755","doi-asserted-by":"publisher","DOI":"10.4048\/jbc.2014.17.4.363"},{"key":"bibr6-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/135819"},{"key":"bibr7-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq607"},{"key":"bibr8-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1517\/14740331003627441"},{"key":"bibr9-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2010.09.001"},{"key":"bibr10-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq096"},{"key":"bibr11-1078155216639755","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.6-5-478"},{"key":"bibr12-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2006.09.002"},{"key":"bibr13-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1016\/S0277-9536(01)00183-6"},{"key":"bibr14-1078155216639755","unstructured":"Ministry of Health. Clinical protocols and therapeutic guidelines in oncology, 1st ed. Bras\u00edlia: Ministry of Health, 2014, pp. 355."},{"key":"bibr15-1078155216639755","unstructured":"New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels, 9th ed. Boston: Little Brown, 1994, pp. 352."},{"key":"bibr16-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910383"},{"key":"bibr17-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.0946"},{"key":"bibr18-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.7045"},{"key":"bibr19-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052122"},{"key":"bibr20-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-012-2039-z"},{"key":"bibr21-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1714-9"},{"issue":"4","key":"bibr22-1078155216639755","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000365950","volume":"9","author":"da Fonseca LG","year":"2014","journal-title":"Breast Care (Basel)"},{"key":"bibr23-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2732-6"},{"key":"bibr24-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2009.04.011"},{"key":"bibr25-1078155216639755","first-page":"634","volume":"99","author":"Farolfi A","year":"2013","journal-title":"Heart Fail"},{"key":"bibr26-1078155216639755","first-page":"1717","volume":"33","author":"Naumann D","year":"2013","journal-title":"Anticancer Res"},{"key":"bibr27-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0498-7"},{"key":"bibr28-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.173"},{"key":"bibr29-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.3.719"},{"key":"bibr30-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2639"},{"key":"bibr31-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601485"},{"key":"bibr32-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.9551"},{"key":"bibr33-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1111\/tbj.12412"},{"key":"bibr34-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm217"},{"key":"bibr35-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.0868"},{"key":"bibr36-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.10.001"},{"key":"bibr37-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70225-0"},{"key":"bibr38-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-3029-0"},{"key":"bibr39-1078155216639755","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)89179-5"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155216639755","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155216639755","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155216639755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:16:46Z","timestamp":1777688206000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155216639755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,15]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1177\/1078155216639755"],"URL":"https:\/\/doi.org\/10.1177\/1078155216639755","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,15]]}}}